| Objective: To investigate the clinical efficacy of recombinant human interferon α2b vaginal effusion capsules alone and in combination with promestriene cream in the treatment of postmenopausal HPV infection,and to analyze whether there is any difference in the efficacy of treating high-risk and low-risk types of postmenopausal HPV infection,so as to provide a basis for the early prevention and treatment of postmenopausal HPV infection patients and a new way of treatment.Methods: Patients with postmenopausal HPV infection who met the inclusion criteria in Qing Hai University Hospital in the past one year were selected for the study,and a total of 190 patients were finally included.Patients in the high-risk interferon group(54 patients)and low-risk interferon group(43 patients)were given recombinant human interferon α2b vaginal effervescent capsules(Sinfonia)for 3 months,and were reviewed after 3months of discontinuation;patients in the high-risk combination HPV group(52 patients)and low-risk combination HPV group(41 patients)were treated with the above-mentioned interferon in combination with vaginal progesterone The patients were treated with interferon as described above,and promestriene cream was applied vaginally for 6 months.The results of patients’ age,years of menopause,pregnancy,delivery,before and after estrogen treatment,before and after HPV treatment,before and after TCT treatment,and before and after treatment of vaginal environment(bacterial density and diversity,dominant bacteria,p H value,hydrogen peroxide,Nugent score)were recorded.Results:1.There was no statistically significant difference(P > 0.05)in the comparison of basic information of each group: age,year of menopause,pregnancy,delivery,before TCT treatment,before flora density treatment,before flora diversity treatment,before Nugent score treatment,before dominant bacteria treatment,before PH treatment,before hydrogen peroxide treatment,and the baseline information was balanced and comparable.2.In terms of the efficacy of HPV,29 of 54 patients in the high-risk interferon group turned negative and 6 improved,with a total effective rate of64.8%;40 of 52 patients in the high-risk combination drug group turned negative and 4 improved,with a total effective rate of 84.6%;24 of 43 patients in the low-risk interferon group turned negative and 7 improved,with a total effective rate of 72.1%;33 of 41 patients in the low-risk combination drug group turned negative and 4 improved,with a total effective rate of 90.2%.There was a statistically significant difference(P<0.05)in the mean HPV efficacy between the combination and interferon alone in both the high-risk and low-risk groups,but there was no statistically significant difference(P>0.05)in the efficacy of the combination or alone in the treatment of postmenopausal HPV infection of high-risk and low-risk types.3.In terms of TCT results: there was no statistically significant difference in TCT results in either HPV high-risk or low-risk patients compared after treatment with the combination of drugs or interferon alone(P>0.05).And the differences before and after treatment in each group were statistically significant(P<0.05).4.In terms of vaginal secretions:In patients with high-risk or low-risk HPV,there were statistically significant differences between the two groups in terms of flora density and diversity,dominant bacteria,PH value,hydrogen peroxide,and Nugent score after and before treatment(P<0.05).5.There was no statistically significant difference in estrogen levels in the combination treatment group before and after treatment(P>0.05).Conclusions: 1.The clinical efficacy of recombinant human interferon combined with promestriene cream in the treatment of postmenopausal HPV infection in the high-risk group or low-risk group was definite and promoted HPV regression,which was better than that of interferon alone in terms of HPV efficacy,and in terms of overall efficiency,the efficiency of the low-risk group was higher than that of the high-risk group,but there was no difference in the mean level of efficacy of the combination group or the interferon group alone in the treatment of patients with high-risk or low-risk HPV infection.In the high-risk and low-risk groups,the combination group improved the vaginal microecological environment(increased flora density and diversity,PH normalization rate,increased predominance and hydrogen peroxide negativity,and decreased Nugent score)compared with the single interferon group,and in the low-risk HPV menopausal patients,the vaginal microecological environment improved better.In this study,the vaginal use of progesterone cream in postmenopausal women did not increase plasma estrogen levels and was safe and effective. |
PDF Full Text Request